Annual Meeting Sessions on Population Health

As the world’s largest professional society of clinicians and scientists dedicated to conquering blood diseases, ASH seeks to expand the availability of hematologic care while promoting the highest standards of excellence in hematology research, training, and practice. Population Health Sessions examine how and why diseases can disproportionally affect some populations and how attendees can navigate those challenges to deliver quality care to all individuals with hematologic diseases and disorders.

For more information about population health and ASH's Commitment to Excellence Through Expansion and Inclusion, please visit ASH's Expansion and Inclusion page.

Additional information about Population Health sessions will be available at a later date.

Jump to:

Education Program

Our Patient Is Pregnant: Comanaging Obstetric Patients With Complex Hematologic Issues During Their Pregnancy and Delivery

Sunday, December 7, 2025, 9:30 a.m. - 10:45 a.m.
Hyatt - Regency Ballroom S

Pregnant women comprise a population with exceptionally challenging sets of problems for the consulting hematologist. This session, held in conjunction with the Foundation for Women & Girls with Blood Disorders will focus on three sets of hematologic problems faced by pregnant women. In many cases, there are no evidence-based guidelines for optimal management, but only expert opinion and case series, making management decisions even more challenging.

Dr. Bethany Samuelson Bannow will present the risks and hemostatic changes associated with pregnancy in individuals with and without bleeding disorders. Essential components of delivery planning in patients with bleeding disorders will be discussed, including mode of delivery and neuraxial anesthesia.

Dr. Donald Arnold will review management of immune thrombocytopenia (ITP) in pregnancy, including management of refractory ITP and what is known about use of thrombopoietin receptor agonists in pregnancy.

Dr. Lydia Pecker will present best practices for management of high-risk pregnancies in patients with sickle cell disease and how to proactively strategize to best improve outcomes for both moms and babies.

Chair:

Alice Ma, MD
University of North Carolina at Chapel Hill
Chapel Hill, NC, United States

Speakers:

Bethany Samuelson Bannow, MD,PhD
Oregon Health and Science University
Portland, OR, United States
Pregnancy Management for Patients with Bleeding Disorders

Donald Arnold, MD
McMaster University
Hamilton, ON, Canada
A Practical Approach to Immune Thrombocytopenia in Pregnancy

Lydia Pecker, MD
Johns Hopkins University
Baltimore, MD, United States
Proactive Management to Improve Outcomes in High-Risk Sickle Cell Disease Pregnancy

Update in Hemophilia Across the Lifespan: Novel Therapies/Gene Therapy/Issues in Older Patients

Monday, December 8, 2025, 10:30 a.m. - 11:45 a.m.
OCCC - W307

Driven by remarkable scientific achievements over the last half-century, the life expectancy of individuals with severe hemophilia has reached that of the general population. Tailoring therapy to each patient’s deficiency, age, clinical circumstances, and life goals requires treating clinicians to be knowledgeable about therapeutic options to support shared decision-making.

This session provides an update on hemophilia across the lifespan, covering the broad array of current therapies, their mechanism of action, and application in clinical practice.

The first talk provides an overview of gene therapy for hemophilia, which has arrived in the clinic with two approved medications — one for hemophilia A and one for hemophilia B. The basics of gene therapy and their application to clinical practice will be addressed. Dr. Guy Young will "deconstruct" gene therapy by explaining the various components and delivery systems, followed by a brief review of approved products, clinical trial results, and a discussion of novel approaches for hemophilia gene therapy under study. Lastly, gene therapy center logistics and patient selection will be presented.

In the second talk, Dr. Mark Reding will discuss the evolution of the treatment landscape over the last decade, and how the introduction of several therapies with novel mechanisms of action has created new challenges for clinicians to select optimal individual treatment. The development of extended half-life factor products, factor VIII mimetics, and rebalancing therapies will be reviewed. This talk emphasizes the treatment consideration complexity and the need for a nuanced approach to patient/family education to align with the shared decision-making model of care.

In the third talk, Dr Lim will provide a discussion on issues related to aging patients with hemophilia. Medical conditions affecting the general population are observed in aging hemophilia patients; these conditions include, but are not limited to, obesity, diabetes, cardiovascular disease, and malignancy. Monitoring, preventative care, and treatment of these conditions often represent gaps in care for the hemophilia population; primary care providers may be hesitant to provide needed interventions and/or patients may have difficulty identifying a consistent primary care provider. Specific issues related to hemophilia sequela, including liver and bone health, gait instability, and risk for falls and fractures, must be considered. The need for adequate support for aging individuals and the potential development of frailty is amplified when continued underlying bleeding disorder treatment is required with other medical conditions. Through current treatment advances that support decreased risk of hemophilia-associated sequela, and increased general health preventative measures, the hemophilia population may realize improved longevity while maintaining “wellness," while also achieving personal goals and best outcomes.

Chair:

Amy Shapiro, MD
Indiana Hemophilia and Thrombosis Center
Indianapolis, IN, United States

Speakers:

Mark Reding, MD
University of Minnesota Medical School
Minneapolis, MN, United States
New Therapies in Hemophilia: Extend the Half-Life, Bypass, or Rebalance?

Guy Young, MD
Children's Hospital Los Angeles
Los Angeles, CA, United States
Deconstructing Gene Therapy in Hemophilia for the Clinician

Ming Lim, MBBCh, MS
University of Utah
Salt Lake City, UT, United States
The Ageing Hemophilia Patient

Industry Forums

Evolving Patient Support Programs: Access, Education and Affordability in Oncology Care

Saturday, December 6, 2025, 8:00 a.m. - 9:00 a.m.
OCCC - W203AB

For in-person participants only back to top

Marquee Sessions

Plenary Scientific Session

Sunday, December 7, 2025, 2:00 p.m. - 4:00 p.m.
OCCC - West Hall D2

Speakers:

Kerry A. Rogers, MD
Ohio State University Hospital
Columbus, OH, United States
Plenary Introducer 1

Othman Al-Sawaf, MD, PhD
University Hospital of Cologne
Cologne, Germany
Fixed-duration versus continuous targeted treatment for previously untreated chronic lymphocytic leukemia: Results from the randomized CLL17 trial

R. Coleman Lindsley, MD, PhD
Dana-Farber Cancer Institute
Boston, MA, United States
Plenary Introducer 4

Andrew Wei, MBBS,PhD
The Walter and Eliza Hall Institute of Medical Research
1g Royal Parade, Parkville , VIC, Australia
Plenary Introducer 6

Amir T. Fathi, MD
Massachusetts General Hospital
Boston, MA, United States
Results from paradigm - a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia

Press Program Presentations

More Than Medicine: Improving Patient Experience and Access

Saturday, December 6, 2025, 7:15 a.m. - 8:15 a.m.
OCCC - W221D

Speaker:

Richard Godby, MD
Mayo Clinic
Rochester, MN, United States
Implementation of a multidisciplinary quality improvement project standardizing an approach to screening and treating iron deficiency in pregnancy

Scientific Program

CARs for Kids: Chimeric Antigen Receptor T-cell Therapy for Childhood Leukemias

Saturday, December 6, 2025, 2:00 p.m. - 3:15 p.m.
OCCC - Tangerine Ballroom F3-4

Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment landscape of pediatric leukemias, achieving remission rates in children with otherwise refractory disease. Yet, despite its promise, significant challenges remain in achieving durable remissions, expanding efficacy beyond B-cell malignancies, and safely applying this approach across diverse leukemia subtypes. This session will explore the latest translational and clinical advances driving the next generation of CAR-T therapies for childhood leukemias. Together, the talks featured in this session will provide a forward-looking view of how cutting-edge CAR-T innovations are reshaping pediatric leukemia treatment—from B-acute lymphoblastic leukemia (ALL) to acute myeloid leukemia (AML)—and paving the way toward broader, more durable cures.

Dr. Sara Ghorashian will review clinical outcomes in relapsed and refractory B-cell ALL and discuss novel strategies to enhance CAR-T efficacy, mitigate relapse, and evaluate the potential for introducing CAR-T earlier in therapy.

Dr. Maksim Mamonkin will address the unique challenges of developing CAR-T therapy for T-cell ALL. His presentation will highlight innovative antigen-targeting approaches, and engineering strategies to overcome T-cell self-death and aplasia, and the most recent results from emerging clinical trials that signal progress in this difficult leukemia subtype.

Dr. Paulina Velasquez will focus on solutions to two critical barriers in AML: antigen heterogeneity and the immunosuppressive tumor microenvironment. She will discuss dual-targeted CAR constructs and preclinical immunocompetent models designed to optimize therapeutic efficacy.

Chair:

Julie Jaffray, MD
Rady Children's Hospital, University of California, San Diego
San Diego, CA, United States

Speakers:

Sara Ghorashian, FRCPath, PhD
Great Ormond Street Institute of Child Health
London, ENG, United Kingdom
CAR T-Cell Breakthroughs: Shaping the Future of B-Cell ALL Treatment

Maksim Mamonkin, PhD
Baylor College of Medicine
Houston, TX, United States
T-Cell ALL Meets CAR-T: Advancements and Breakthroughs

Paulina Velasquez, MD
St. Jude Children's Hospital
Memphis, TN, United States
Harnessing CAR-T: A New Era in AML Treatment

Scientific Spotlight Sessions

Bridging Translational Science and Clinical Trials to Transform Burkitt Lymphoma Research Globally

Monday, December 8, 2025, 10:30 a.m. - 11:45 a.m.
OCCC - Tangerine Ballroom F2

The treatment of Burkitt’s lymphoma (BL) is a testament to the profound curative potential of combination chemotherapy, and most patients are cured with modern treatment approaches that utilize intensive chemotherapy along with aggressive supportive care. Still, gaps remain for patients unable to tolerate intensive chemotherapy, for those with disease that become resistant to chemotherapy, and for those who live in areas of the world with fewer supportive care resources. This session will examine the current understanding of the molecular biology of BL, the tumor microenvironment and how this might influence clinical and translational research efforts. It will also explore and highlight significant efforts in Sub-Saharan Africa that attempt to bridge the gap and improve outcomes globally.

Dr. Mark Roschewski will describe the history of BL and its emergence as one of the most sensitive subtypes of lymphoma to chemotherapy. More recently, the field has come to understand molecular subtypes of BL that may have differential response to immunotherapy and/or targeted agents. Dr. Roschewski will also address the role of the tumor microenvironment and its relevance in clinical outcomes.

Dr. Clara Chamba will present progress from the Aggressive Infection-Related East African Lymphoma (AI-REAL) study, focusing on innovative approaches to diagnosing and managing BL in Sub-Saharan Africa. She will highlight minimally invasive diagnostic strategies, share key insights from recent validation efforts, and discuss lessons learned in building sustainable capacity for lymphoma care in resource-limited settings. Dr. Chamba will also reflect on the collaborative model that brought together international partners and local institutions to address diagnostic delays. Finally, she will outline the broader implications of this work for advancing equitable access to timely cancer diagnosis across low- and middle-income countries.

Speakers:

Mark Roschewski, MD
NIH/NIC
Bethesda, MD, United States
Translating Knowledge about Burkitt Lymphoma Genomics and Microenvironment into Novel Clinical Trials

Clara Chamba
Muhimbili University of Health and Allied Sciences
Dar-es-Salaam, Tanzania
Burkitt Lymphoma Research in Africa: Overcoming Challenges and Unlocking Translational Potential

Scientific Workshops

Disease Severity Scoring in Sickle Cell Disease

Friday, December 5, 2025, 3:05 p.m. - 3:45 p.m.
OCCC - W315

Speakers:

Jane Hankins, MD,MS
St Jude Children's Research Hospital
Memphis, TN, United States
Moderator Introduction: Topic Only

Elizabeth Klings, MD
Boston University
Boston, MA, United States
Prior Disease Severity Scoring Systems

Courtney Thornburg, MD, MS
Rady Children's Health - Orange County
Orange, CA, United States
Defining Disease Severity for NHLBI Innovative Trials

Tarun Aurora, MD, MSCI
Emory University
Atlanta, GA, United States
A New Severity Classification System (SCOGS)

Special-Interest Sessions

ASH Clinical Practice Guidelines on Diagnosis of Iron Deficiency with and without Anemia

Saturday, December 6, 2025, 4:00 p.m. - 5:30 p.m.
Hyatt - Regency Ballroom OPQ

In this session, speakers will highlight recommendations from the upcoming ASH guidelines on diagnosis of iron deficiency and will discuss important considerations for the application of the recommendations in practice.

Chair:

Jacquelyn Powers, MD
Texas Children's Hematology Center
Houston, TX, United States

Speakers:

Imo Akpan, MD
Columbia University Irving Medical Center
New York, NY, United States
Ferritin, TSAT, and how low is too low: Diagnosis of iron deficiency in adults

Layla Van Doren, MD,MBA
Yale School of Medicine
New Haven, CT, United States
Menstruating individuals: Evidence-based ferritin thresholds

Michelle Sholzberg, MD
University of Toronto
Toronto, ON, Canada
Screening and defining iron deficiency in pregnant individuals

ASH Clinicians in Practice Lunch: Access to Critical Drugs: The Causes, Costs, and Campaigns

Sunday, December 7, 2025, 11:15 a.m. - 12:30 p.m.
Hyatt - Florida Ballroom

Chair:

Mary-Elizabeth Percival, MD
Seattle Cancer Care Alliance
Seattle, WA, United States

Speakers:

Thomas Roades
Duke-Margolis Institute for Health Policy
Durham, NC, United States
The interactions of the pharmaceutical system and how the competing demands of different stakeholders can influence cost and shortages

Emily Mackler
YesRX
Ann Arbor, MI, United States
Combatting drug shortages with drug repository programs

Brooke Boring
Hematology/Oncology Pharmacy Association
Milwaukee, WI, United States
Advocacy at the federal and state level and how practitioners can get engaged

Celebrating Diverse Voices: Enriching Hematology Lunch

Monday, December 8, 2025, 12:00 p.m. - 1:30 p.m.
Hyatt - Florida Ballroom A

This is a community-building and networking event for members from an expansive and inclusive group of communities attending the meeting. The event is hosted by the Committee on Advancing Excellence and Population Health and aims to create space for these communities to learn more about the differing experiences and needs across communities and create a sense of belonging and allyship. This year’s event will include inspiring remarks from a fellow member and networking opportunities throughout. back to top

How Can Community-Based and Academic Hematologists Foster Clinical Trial Participation as Part of Patient Care?

Sunday, December 7, 2025, 9:30 a.m. - 11:00 a.m.
Hyatt - Plaza Int'l HIJK

Patients often learn about clinical trials from their healthcare providers. However, the barriers to trial participation include: patients not being offered trials; physicians not having the capacity to effectively navigate clinicaltrials.gov and enroll patients; and community-based physicians are often not engaged (or engaged early enough to make a meaningful impact) in the clinical trial life cycle. This session will (1) address barriers that practicing hematologists face offering trials to patients, (2) provide practical solutions to overcome these barriers and (3) highlight best practices to engage patients and increase participation in trials.

Speakers will consist of a mix of practicing hematologists as well as other stakeholders in the clinical trial enterprise sharing their perspectives on the issue. The session will conclude with the speakers providing practical tactics that the audience can take to enhance access, inclusivity, and ultimately representation in hematology trials.

Chair:

Leonard Valentino
Rush University Medical Center
New York, NY, United States

Speakers:

Leonard Valentino
Rush University Medical Center
New York, NY, United States
Challenges to Clinical Trial Participation

Lanre Tunji-Ajayi, MS
Sickle Cell Awareness Group of Ontario
Pickering, ON, Canada
Patient Perspective

John M. M. Burke, MD
Rocky Mountain Cancer Centers
Aurora, CO, United States
Engagement of Community Physicians in Clinical Trials

Fabio Dennstaedt
University Hospital and University of Bern
Bern, Switzerland
Moving Patients to Participants in Hematology Clinical Trials

Stephanie Valer Seremetis, MD
Novo Nordisk A/S
Plainsboro, NJ, United States
Industry Perspective

Alysha Croker
Health Canada
Ottawa, ON, Canada
Government Perspective

Jeffrey Keefer, MD,PhD
IQVIA
Keswick, VA, United States
Contract Research Organization Perspective

Michelle Feige
Accreditation of Human Research Protection Programs (AAHRPP)
Washington, DC, United States
Institutional Review Board Perspective

Leveraging Genetic Diversity in Preclinical Discovery to Guide Precision Medicine

Saturday, December 6, 2025, 9:30 a.m. - 10:45 a.m.
OCCC - W314

Consideration for variability in the constitutional DNA in medical research presents a unique opportunity to uncover novel biology, identify population-specific risk factors, and develop tailored therapies. By embracing the genetic and environmental variations across populations, we can unlock new avenues for innovation. While the clinical impact of variations in the somatic genetic profile, clinical presentation and survival prognostications are recognized, there is an unmet need to better understand the underlying biology of sometimes contrasting genotype-phenotype associations originating from varying germline genetic ancestries. This is caused by difficulties of biologically faithful functionalization approaches, and also limitations in the availability of suitable model organisms.

This session will present examples of bench-to-bedside translations, new model systems and basic research tools that have broad applicability for both basic and translational researchers. It may catalyze collaborations between translational researchers and basic scientists. In addition, the session aims to bridge the gap between clinical practice and basic research by exploring the critical role of genetic variation as a proxy for advancing precision medicine.

Attendees of the session will leave with an appreciation for the importance of considering genetic variation in research and cross-disciplinary partnerships to drive meaningful advances in patient treatment and survival.

Speakers:

Kellie Machlus, PhD
Harvard Medical School
Boston, MA, United States
Discovery Based on Population Structure: How to Faithfully Understand and Functionalize Novel Treatments

Adam J de Smith
University of Southern California Keck School of Medicine
Los Angeles, CA, United States
Decoding Bias in Disease Risk: The Role of Ancestry and Genomic Variant Clustering

Jesse Boehm Jr
MIT
Cambridge, MA, United States
Moving Towards Precision Medicine: Influence of Germline and Ancestry on Preclinical Target Discovery

LGBTQIA+ Community Networking Brunch

Sunday, December 7, 2025, 11:00 a.m. - 12:30 p.m.
Hyatt - Plaza Int'l DEFG

This is a community-building and networking event for members of the LGBTQIA+ community attending the meeting. The event is hosted by the Committee on Advancing Excellence and Population Health and aims to create a sense of belonging and allyship. This year’s event will include breakout group discussion on mentorship, community building, and career advancement followed by speed networking. back to top

Medical Educators' Symposium

Sunday, December 7, 2025, 7:00 a.m. - 9:00 a.m.
Hyatt - Plaza Int'l DEFG

The ASH 2025 Medical Educators Symposium will be focused on cultural evolutions, both for academic medical practice and trainee education. Medical education and patient care are rapidly transforming from the perspective of inclusivity, cultural humility, and mixed methods of teaching. Come hear from educational experts about how to better engage trainees through revolutionary multimedia approaches as well. Regardless of your training level or faculty rank, come join the conversation and share your perspectives. Everyone's voice matters!

Chair:

Alexander Boucher, MD
University of Minnesota
Minneapolis, MN, United States

Speakers:

Robert Stern, MD
Dana-Farber Cancer Institute
Boston, MA, United States
General Session 1: The Evolving Landscape of Cultural Terminology in Hematology Part 1

Laura DeCastro, MD
University of Pittsburgh Medical Center
Pittsburgh, PA, United States
General Session 1: The Evolving Landscape of Cultural Terminology in Hematology Part 2

Jean M. Connors, MD
Harvard Medical School
Boston, MA, United States
General Session 2: Tips and Tricks to Efficiently Handle Knowledge Gathering Part 1

Jori May, MD
University of Alabama at Birmingham
Birmingham, AL, United States
General Session 2: Tips and Tricks to Efficiently Handle Knowledge Gathering Part 2

Ronak Mistry, DO
University of Pennsylvania
Philadelphia, PA, United States
General Session 3: Content Creation as Medical Educators Part 1

Ajay Major, MD, MBA
University of Colorado Cancer Center
Denver, CO, United States
General Session 3: Content Creation as Medical Educators Part 2

Alexander Boucher, MD
University of Minnesota
Plymouth, MN, United States
General Session Q&A

Marina Heskel, MD
University of California San Francisco
San Francisco, CA, United States
Breakout 2: Mixed Methods Educational Strategies for All Learners - Facilitator A

Reed E. Drews, MD
Harvard Medical School
Boston, MA, United States
Breakout 2: Mixed Methods Educational Strategies for All Learners - Facilitator B

Rohini Jain, MD
University of California San Francisco
San Francisco, CA, United States
Breakout 3: Cultural Humility in Hematology Care - Facilitator B

Sana Saif Ur Rehman, MD
Washington University in St Louis
Saint Louis, MO, United States
Breakout 4: Innovation in Education for the Current Generation - Facilitator A

Thomas Deloughery, MD
Oregon Health and Science University
Portland, OR, United States
Breakout 4: Innovation in Education for the Current Generation - Facilitator B

Treating Fairly Rounds Lunch

Sunday, December 7, 2025, 11:30 a.m. - 12:30 p.m.
Hyatt - Manatee Spring

The Treating Fairly Rounds Lunch session will

Introduce the role of language (and cultural diversity) in the delivery of health care for non-English speaking populations
Discuss the impact of language barrier on the utilization of old and novel therapies, patient compliance, safety, and disease outcomes
Present potential solutions to overcome some of the challenges posed by language barriers and improve healthcare quality and patient outcomes.

Speakers:

Rahma Warsame, MD
Mayo Clinic
Rochester, MN, United States
Healthcare Access to Non-English Speaking Populations - Presenter 1

Cesar Rodriguez Valdes, MD
Icahn School of Medicine at Mount Sinai
New York, NY, United States
Healthcare Access to Non-English Speaking Populations - Presenter 2

Updated ASH Clinical Practice Guidelines on Acute Myeloid Leukemia (AML) in Older Adults

Sunday, December 7, 2025, 9:30 a.m. - 11:00 a.m.
OCCC - W414CD

In this session, speakers will highlight recommendations from the updated ASH guidelines on AML in older adults and will discuss important considerations for the application of the recommendations in practice.

Chair:

Mikkael Sekeres, MD
Sylvester Comprehensive Cancer Center, University of Miami
Miami, FL, United States

Speakers:

Kah Poh (Melissa) Loh, MD, MS
University of Rochester Medical Center
Rochester, NY, United States
Treatment Options for Older Adults with AML: Recommendations on Low-Dose Cytarabine, Azacitidine, and Decitabine Regimens as Monotherapy or Combinations

Luca Malcovati, MD
University of Pavia and IRCCS S. Matteo Hospital Foundation
Pavia, PV, Italy
Treatment Options for Older Adults with AML and IDH1/IDH2 Mutations: Recommendations on HMA Monotherapy, Combinations with Venetoclax, and Targeted Therapies

Maria R. Baer, MD
University of Maryland
Baltimore, MD, United States
Recommendations for Treatment for Older Adults with AML and FLT3 Mutations

Trainee Activities and Services

Career Development Lunch

Saturday, December 6, 2025, 11:15 a.m. - 12:15 p.m.
Hyatt - Windermere Ballroom

This session provides an intimate venue for trainees to meet with leaders in hematology to discuss careers in the wide array of practice areas within hematology, including basic, clinical, and translational research, PhD careers, careers in industry settings, and careers in private and clinical practice. There will are multiple tables dedicated to each career area and one faculty member at each table leading the discussion. A boxed lunch is provided. This is a first come, first served event that is usually very-well attended. The full list of topics covered are: Adult BMT/Cellular Therapy; Pediatric BMT/CAR-T; Adult Clinical Malignant Hematology; Adult Clinical Classical Hematology; Pediatric Clinical Classical Hematology; Pediatric Hematology/Oncology; Private Practice Hematology; Government Careers; Industry Careers; Laboratory and Translational Hematology; Medical Educators in Hematology; PhD Careers; International Opportunities Hematology; Women's Health; Medical Informatics and AI; Lifespan Hematology; Geriatric Hematology; International Graduate Hematology; Administrative Careers in Hematology; and Hematology-Focused Fellowship Training Program.

Chair:

Leidy Isenalumhe, MD, MS
Moffitt Cancer Center
Lutz, FL, United States

Speakers:

Rawan Faramand, MD
Moffitt
Tampa, FL, United States
Adult BMT/Cellular Therapy

Lori Muffly, MD
Stanford University
Stanford, CA, United States
Adult BMT/Cellular Therapy

Gunjan L. Shah, MD, MS
Memorial Sloan Kettering
New York, NY, United States
Adult BMT/Cellular Therapy

Azra Borogovac
City of Hope
Irvine, CA, United States
Adult BMT/Cellular Therapy

Neel Bhatt, MBBS,MPH
Fred Hutch
Seattle, WA, United States
Pediatric BMT/CAR-T

Kris Mahadeo
Duke University
Houston, TX, United States
Pediatric BMT/CAR-T

Dorothea Douglas, MD
Nemours
Orlando, FL, United States
Pediatric BMT/CAR-T

Ajay Major, MD, MBA
University of Colorado Cancer Center
Denver, CO, United States
Adult Clinical Malignant Hematology

Hira Shaikh, MD
University of Iowa Caver College of Medicine
Iowa City, IA, United States
Adult Clinical Malignant Hematology

Jennifer L. Crombie, MD
Dana Farber Cancer Institute
Boston, MA, United States
Adult Clinical Malignant Hematology

Gabriela Soriano Hobbs, MD
Massachusetts General Hospital
Boston, MA, United States
Adult Clinical Malignant Hematology

Ronak Mistry, DO
University of Pennsylvania
Philadelphia, PA, United States
Adult Clinical Classical Hematology

Alice Ma, MD
University of North Carolina at Chapel Hill
Chapel Hill, NC, United States
Adult Clinical Classical Hematology

Peter Kouides, MD
University of Rochester
Rochester, NY, United States
Adult Clinical Classical Hematology

Thomas Coates, MD
Children's Hospital of Los Angeles
Los Angeles, CA, United States
Pediatric Clinical Classical Hematology

Neha Bhasin, MD
Beinoff Children's
Oakland, CA, United States
Pediatric Clinical Classical Hematology

Melissa Rose, DO
Nationwide Children’s Hospital
Columbus, OH, United States
Pediatric Clinical Classical Hematology

Deepa Bhojwani, MD
Children's Hospital of Los Angeles
Los Angeles, CA, United States
Pediatric Hematology/Oncology

Rayne Rouce, MD
Texas Children's Hospital
Houston, TX, United States
Pediatric Hematology/Oncology

Venee N. Tubman, MD MMSc
Texas Children's Cancer and Hematology Centers
Houston, TX, United States
Pediatric Hematology/Oncology

Camila Masias, MD,MPH
Miami Cancer Institute
Miami, FL, United States
Community Practice Hematology

Matthew Ulrickson, MD
MD Anderson Medical Center/Banner Health
Gilbert, AZ, United States
Community Practice Hematology

Donna DiMichele, MD
NIH
Washington, DC, United States
Government Careers

Relja Popovic, PhD
AbbVie
North Chicago, IL, United States
Industry Careers

Weili Sun
Janssen Pharmaceutical
Los Angeles, CA, United States
Industry Careers

Nina Shah, MD
AstraZeneca
South San Francisco, CA, United States
Industry Careers

Olga Guryanova
University of Florida
Gainesville, FL, United States
Laboratory and Translational Hematology

Bob Lowenberg, MD,PhD
Erasmus University Medical Center
Rotterdam, Netherlands
Laboratory and Translational Hematology

Sherine F Elsawa, PhD
University of New Hampshire
Durham, NH, United States
Laboratory and Translational Hematology

Lori Rosenstein, MD
Gunderson Health
La Crosse, WI, United States
Medical Education in Hematology

Catherine E McGuinn, MD
Cornell University
New York, NY, United States
Medical Education in Hematology

Leslie Ellis, MD
Wake Forest University School of Medicine
Winston Salem, NC, United States
Medical Education in Hematology

Anna Beaudin, PhD
University of Utah
Salt Lake City, UT, United States
PhD Careers

Ze Zheng
Versiti Blood Research Institute
Milwaukee, WI, United States
PhD Careers

Andres Gomez-De Leon Jr, MD
Universidad Autónoma de Nuevo León
Monterrey, Mexico
International Opportunities in Hematology

Eugenia Asare, MD, MBChB
Ghana Institute of Clinical Genetics
Accra, Ghana
International Opportunities in Hematology

Bethany Samuelson Bannow, MD,PhD
Oregon Health and Science University
Portland, OR, United States
Women's Health

Alecia Nero, MD
UT Southwestern Medical Center
Dallas, TX, United States
Women's Health

Becky Zon, MD
Brigham and Women's Hospital
West Roxbury, MA, United States
Women's Health

Swami P. Iyer, MD
MD Anderson Cancer Center
Houston, TX, United States
Medical Informatics and AI

Neil Zakai
University of Vermont
Burlington, VT, United States
Medical Informatics and AI

William Wood, MD, MPH
University of North Carolina At Chapel Hill Hospital
Chapel Hill, NC, United States
Medical Informatics and AI

Leidy Isenalumhe, MD, MS
Moffitt Cancer Center
Lutz, FL, United States
Lifespan Hematology

Dan Hart
Roche
Welwyn Garden City, England, United Kingdom
Lifespan Hematology

Julie Kanter, MD
University of Alabama at Birmingham
Birmingham, AL, United States
Lifespan Hematology

Maya Abdallah, MD
Boston University
Boston, MA, United States
Geriatric Hematology

Hira Mian, MD
McMaster University
Hamilton, ON, Canada
Geriatric Hematology

Tanya Wildes, MD,MSc
University of Nebraska
Omaha, NE, United States
Geriatric Hematology

Tania Jain, MBBS
Johns Hopkins University
Baltimore, MD, United States
International Graduate Hematology

Saad Z. Usmani, MD
Memorial Sloan Kettering Cancer Center
New York, NY, United States
International Graduate Hematology

Jessica Maria Stempel, MD, MHS
Yale School of Medicine
New Haven, CT, United States
International Graduate Hematology

Ana Antun, MD
Emory University
Decatur, GA, United States
Hematology-Focused Fellowship Training Program

Reed E. Drews, MD
Harvard Medical School
Boston, MA, United States
Hematology-Focused Fellowship Training Program

Amy Zhou, MD
Washington University School of Medicine
Saint Louis, MO, United States
Hematology-Focused Fellowship Training Program

Yvonne Efebera, MD, MPH
Ohio Health
Columbus, OH, United States
Administrative Careers in Hematology

John Byrd, MD
University of Cincinnati
Cincinnati, OH, United States
Administrative Careers in Hematology

Usha S Perepu
UT Health San Antonio
San Antonio, TX, United States
Administrative Careers in Hematology

Trainee Didactic Session: Outcomes Research in Hematology

Monday, December 8, 2025, 12:15 p.m. - 1:15 p.m.
OCCC - W308

In this educational session, speakers will discuss their approach to outcomes research by walking through specific examples and successful strategies to tackle large data. Speakers will discuss the where/when/how/why of comparative effectiveness research, including systematic reviews, and how it can inform future studies and current clinical practice. In addition, they will explain the advantages and disadvantages of population-based research, and how to go about making your own database.

Chair:

Reshma Ramlal
Moffitt Cancer Center
Tampa, FL, United States

Adam S Kittai, MD
Icahn School of Medicine at Mount Sinai
New York, NY, United States

Speakers:

Scott Huntington, MD, MPH
Yale School of Medicine
New Haven, CT, United States
Outcomes Research in Hematology

Mengyang Di, MD, PhD
University of Washington
Seattle, WA, United States
Outcomes Research in Hematology

Treating Fairly Talks

Treating Fairly Talks: A Holistic Approach: The Sickle Cell Foundation of Georgia, Inc. & The Sickle Cell Sanctuary

Monday, December 8, 2025, 8:30 a.m. - 9:00 a.m.
OCCC - Hall C ASH Studio

As part of our commitment to excellence through expansion and inclusion, the American Society of Hematology (ASH) is offering the ASH Treating Fairly Talks. This inclusive space is designed to help attendees recognize the drivers of differing outcomes for various populations as viewed through the hematology lens and provide tools to make changes in their institutions. These sessions will include a short expert commentary followed by facilitated conversations about actions that can be taken to drive change at your institution. The Treating Fairly Talks will take place at the ASH Studio, located in ASH Central (Orange County Convention Center, West Hall C).

Ms. Tabatha McGee, CEO of the Sickle Cell Foundation of Georgia, Inc., will present on successful community-centric initiatives for sickle cell disease.

Speakers:

Treating Fairly Talks: A Holistic Approach: The Sickle Cell Foundation of Georgia, Inc. & The Sickle Cell Sanctuary

Sunday, December 7, 2025, 1:30 p.m. - 2:00 p.m.
OCCC - Hall C ASH Studio

Ms. Tabatha McGee, CEO of the Sickle Cell Foundation of Georgia, Inc., will present on successful community-centric initiatives for sickle cell disease.

Speakers:

Tabatha McGee
Sickle Cell Sanctuary
Atlanta, GA, United States
A Holistic Approach: The Sickle Cell Foundation of Georgia, Inc. and The Sickle Cell Sanctuary

Treating fairly Talks: Breaking Barriers in Blood Cancer: Transforming Access and Outcomes Across Populations

Monday, December 8, 2025, 12:00 p.m. - 12:30 p.m.
OCCC - Hall C ASH Studio

Dr. Tina Bhatnagar will present on the impact of geography on care.

Speaker:

Bhavana Bhatnagar, DO
West Virginia University Cancer Institute, Wheeling Hospital
Wheeling, WV, United States
Breaking Barriers in Blood Cancer: Transforming Access and Outcomes Across Populations

Treating Fairly Talks: Breaking Barriers in Blood Cancer: Transforming Access and Outcomes Across Populations

Sunday, December 7, 2025, 11:00 a.m. - 11:30 a.m.
OCCC - Hall C ASH Studio

Dr. Tina Bhatnagar will present on the impact of geography on care.

Speaker:

Treating Fairly Talks: Breaking Financial Barriers to Care Through Affordable Innovation

Saturday, December 6, 2025, 3:30 p.m. - 4:00 p.m.
OCCC - Hall C ASH Studio

As part of our commitment to excellence through expansion and inclusion, the American Society of Hematology (ASH) is offering the ASH Treating Fairly Talks. These sessions will take place at the ASH Studio, located in ASH Central (Orange County Convention Center, West Hall C). This inclusive space is designed to help attendees recognize the drivers of differing outcomes for various populations as viewed through the hematology lens and provide tools to make changes in their institutions. These sessions will include a short expert commentary followed by facilitated conversations about actions that can be taken to drive change at your institution.

Dr. Andres Gomez-De Leon will present on the financial factors to accessing care.

Speakers:

Treating Fairly Talks: Breaking Financial Barriers to Care Through Affordable Innovation

Monday, December 8, 2025, 1:00 p.m. - 1:30 p.m.
OCCC - Hall C ASH Studio

Dr. Andres Gomez-De Leon will present on the financial factors to accessing care.

Speakers:

Andres Gomez-De Leon Jr, MD
Universidad Autónoma de Nuevo León
Monterrey, Mexico
Breaking Financial Barriers to Care Through Affordable Innovation

Treating Fairly Talks: From Precision Medicine to Personalized Care: Meeting Patients Where They Are

Saturday, December 6, 2025, 1:30 p.m. - 2:00 p.m.
OCCC - Hall C ASH Studio

Dr. Eneida Nemecek will present on tailoring care for optimal patient outcomes.

Speaker:

Treating Fairly Talks: From Precision Medicine to Personalized Care: Meeting Patients Where They Are

Sunday, December 7, 2025, 9:00 a.m. - 9:30 a.m.
OCCC - Hall C ASH Studio

Dr. Eneida Nemecek will present on tailoring care for optimal patient outcomes.

Speaker:

Eneida Nemecek, MD
OHSU Knight Cancer Institute
Portland, OR, United States
From Precision Medicine to Personalized Care: Meeting Patients Where They Are

Treating Fairly Talks: Impact of Geography on Care

Saturday, December 6, 2025, 11:00 a.m. - 11:30 a.m.
OCCC - Hall C ASH Studio

Dr. Norma Ada will present on the impact of geography on care.

Speakers:

Treating Fairly Talks: Impact of Geography on Care

Monday, December 8, 2025, 10:00 a.m. - 10:30 a.m.
OCCC - Hall C ASH Studio

Dr. Norma Ada will present on the impact of geography on care.

Speakers:

Norma Ada
Medical Associates of the Pacific, LLC
Saipan, MP, Northern Mariana Islands
Impact of Geography on Care

Treating Fairly Talks: Promoting Language Equity in Care and Research

Saturday, December 6, 2025, 9:00 a.m. - 9:30 a.m.
OCCC - Hall C ASH Studio

Dr. Alisa Khan will present on the importance of language on outcomes of care.

Speakers:

Treating Fairly Talks: Promoting Language Equity in Care and Research

Sunday, December 7, 2025, 4:00 p.m. - 4:30 p.m.
OCCC - Hall C ASH Studio

Dr. Alisa Khan will present on the importance of language on outcomes of care.

Speakers:

Alisa Khan
Harvard Medical School
Boston, MA, United States
Promoting Language Equity in Care and Research

67th ASH Annual Meeting and exposition

Registration for ASH members, non-members, groups, exhibitors, and media is now open!